Abstract:In order to clearly define the features of Shwachman-Diamond syndrome (SDS) in Chinese children, this article analyzes and summarizes the epidemiology, clinical features, and key points in the diagnosis and treatment of SDS in Chinese children with review of the clinical data of 27 children with SDS from related articles published previously. A comparative analysis was made between the Chinese and international data related to childhood SDS. The results showed a male/female ratio of about 2:1 in the Chinese children with SDS, with an age of onset of < 1 month to 5 years (median 1 month) and an age of 3 months to 12 years (median 12 months) at the time of confirmed diagnosis. Reductions in peripheral blood cells due to myelopoiesis inhibition were observed in all 27 children with SDS, among whom 93% had neutropenia. Chronic diarrhea (85%), liver damage (78%), and short stature (83%) were the three main clinical features of SDS. Supplementation of pancreatin and component blood transfusion may temporarily alleviate the disease, while allogeneic hematopoietic stem cell transplantation is still an effective radical treatment. The comparative analysis of the Chinese and oversea data showed that compared with those in the European and American countries, the children with SDS in China had significantly higher incidence rates of chronic diarrhea, reductions in peripheral blood cells (three lineages), and liver damage, and there were also differences in the type of mutant genes.
TAN Li-Qun,FU Xiao-Yan,XIE Xiao-Tian. Clinical features, diagnosis, and treatment of Chinese children with Shwachman-Diamond syndrome[J]. CJCP, 2020, 22(5): 505-511.
Bezzerri V, Cipolli M. Shwachman-Diamond syndrome:molecular mechanisms and current perspectives[J]. Mol Diagn Ther, 2019, 23(2):281-290.
[2]
Liu Y, Liu F, Cao Y, et al. Shwachman-Diamond syndrome protein SBDS maintains human telomeres by regulating telomerase recruitment[J]. Cell Rep, 2018, 22(7):1849-1860.
[3]
Valli R, Vinti L, Frattini A. Shwachman-Diamond syndrome:diagnosis, pathogenesis and prognosis[J]. Exp Opin Orphan Drug, 2017, 5(10):753-767.
[4]
Dror Y, Donadieu J, Koglmeier J, et al. Draft consensus guidelines for diagnosis and treatment of Shwachman-Diamond syndrome[J]. Ann N Y Acad Sci, 2011, 1242:40-55.
[5]
Mercuri A, Cannata E, Perbellini O, et al. Immunophenotypic analysis of hematopoiesis in patients suffering from Shwachman-Bodian-Diamond syndrome[J]. Eur J Haematol, 2015, 95(4):308-315.
[6]
Minelli A, Nicolis E, Cannioto Z, et al. Incidence of Shwachman-Diamond syndrome[J]. Pediatr Blood Cancer, 2012, 59(7):1334-1335.
[7]
Shimosato Y, Tanoshima R, Tsujimoto SI, et al. Association of isochromosome (7)(q10) in Shwachman-Diamond syndrome with the severity of cytopenia[J]. Clin Case Rep, 2017, 6(1):125-128.
[8]
Wegman-Ostrosky T, Savage SA. The genomics of inherited bone marrow failure:from mechanism to the clinic[J]. Br J Haematol, 2017, 177(4):526-542.
[9]
Bezzerri V, Vella A, Calcaterra E, et al. New insights into the Shwachman-Diamond syndrome-related haematological disorder:hyper-activation of mTOR and STAT3 in leukocytes[J]. Sci Rep, 2016, 6:33165.
[10]
Nelson AS, Myers KC. Diagnosis, treatment, and molecular pathology of Shwachman-Diamond syndrome[J]. Hematol Oncol Clin North Am, 2018, 32(4):687-700.
[11]
Warren AJ. Molecular basis of the human ribosomopathy Shwachman-Diamond syndrome[J]. Adv Biol Regul, 2018, 67:109-127.
Ikuse T, Kudo T, Arai K, et al. Shwachman-Diamond syndrome:nationwide survey and systematic review in Japan[J]. Pediatr Int, 2018, 60(8):719-726.
[27]
Delaporta P, Sofocleous C, Economou M, et al. The Greek Registry of Shwachman-Diamond syndrome:molecular and clinical data[J]. Pediatr Blood Cancer, 2017. DOI:10.1002/pbc.26630. Epub ahead of print.
[28]
Myers KC, Bolyard AA, Otto B, et al. Variable clinical presentation of Shwachman-Diamond syndrome:update from the North American Shwachman-Diamond Syndrome Registry[J]. J Pediatr, 2014, 164(4):866-870.
[29]
Sakaguchi H, Nakanishi K, Kojima S. Inherited bone marrow failure syndromes in 2012[J]. Int J Hematol, 2013, 97(1):20-29.
[30]
Mamrak NE, Shimamura A, Howlett NG. Recent discoveries in the molecular pathogenesis of the inherited bone marrow failure syndrome Fanconi anemia[J]. Blood Rev, 2017, 31(3):93-99.
[31]
Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia[J]. Br J Haematol, 2016, 172(2):187-207.
Li F, Li W, Qiao X, et al. Clinical features of dyskeratosis congenita in mainland China:case reports and literature review[J]. Int J Hematol, 2019, 109(3):328-335.
[38]
Triot A, Järvinen PM, Arostegui JI, et al. Inherited biallelic CSF3R mutations in severe congenital neutropenia[J]. Blood, 2014, 123(24):3811-3817.
[39]
Isaev AA, Deev RV, Kuliev A, et al. First experience of hematopoietic stem cell transplantation treatment of Shwachman-Diamond syndrome using unaffected HLA-matched sibling donor produced through preimplantation HLA typing[J]. Bone Marrow Transplant, 2017, 52(9):1249-1252.
[40]
Park M, Lee YH, Kang HR, et a1. Unrelated donor cord blood transplantation for non-malignant disorders in children and adolescents[J]. Pediatr Transplant, 2014, 18(2):221-229.
[41]
Pichler J, Meyer R, Köglmeier J, et al. Nutritional status in children with Shwachman-Diamond syndrome[J]. Pancreas, 2015, 44(4):590-595.